The following is a summary of the Henry Schein, Inc. (HSIC) Q3 2024 Earnings Call Transcript:

Financial Performance:

• Henry Schein reported Q3 2024 global sales of $3.2 billion with a growth of 0.4% year-over-year, driven largely by acquisitions.

• Non-GAAP EPS for Q3 2024 increased, now forecasted between $4.74 to $4.82, reflecting better than expected financial results.

• GAAP net income for Q3 2024 was $99 million or $0.78 per diluted share, compared to the previous year's $137 million or $1.05 per diluted share.

Business Progress:

• The introduction of the BioHorizons Tapered Pro Conical implant in the U.S. helped drive mid-single-digit sales growth.

• Launch of the global e-commerce platform in the UK and Ireland, with plans to expand to the US market next year.

• Continued investment in high-growth, high-margin businesses, expecting these segments to exceed 40% of operating income target for fiscal 2024.

• Restructuring efforts, including in the orthodontic business with transition to Smilers brand and cost reductions in distribution and technology areas.

Opportunities:

• Positive feedback and initial success from the newly launched global e-commerce platform suggest potential for significant market penetration and customer engagement as it expands.

• The introduction of high-margin products like the BioHorizons implant and SmartShape Healers suggests potential for increased market share and customer base expansion.

Risks:

• Sales impact from ongoing migration to generic alternatives and less demand for respiratory diagnostic products and flu COVID vaccines.

• Ongoing recovery from last year's cyber incident, indicating potential vulnerabilities and past disruptions that might affect customer confidence and operational stability.

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.